6. AstraZeneca

Total Ad Spend: $209.4 million
Television: $156.5 million
Magazine: $41 million
Other: $11.8 million

With stomach drug Nexium facing a patent loss, AstraZeneca ($AZN) pushed it hard last year, as well as its best-selling drug, cholesterol-fighter Crestor. It wasn't enough to keep both from losing ground, with sales declines of 6% and 3% respectively.

In the spotlight

Nexium, $57.6 million
Symbicort, $57.3 million
Crestor, $51.5 million



Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.